Keeping Your Informed 

In a significant development within the gene editing arena, Intellia Therapeutics has announced its decision to opt out of a hemophilia B program, relinquishing control of CRISPR/Cas9-based gene editing work on factor IX treatments to its partner, Regeneron. While this move shifts the responsibility to Regeneron, it is expected to have minimal impact on the latter's pipeline or immediate strategy, as confirmed by a spokesperson to Fierce Biotech. Regeneron remains steadfast in its commitment to advancing the program, undeterred by Intellia's withdrawal. To read more in this article, click here.